| Chiome Bioscience–Minapharm: GlymaxX technology, 201710– service + license cell line developm for antibody production applying GlymaxX by ProBioGen |
2017-10-05 |
| R-Biopharm–EuroProxima: research antibodies, 201710 acquisition of research antibody line from EuroProxima BV by Progen Biotechnik GmbH |
2017-10-05 |
| Boehringer–Siamab Therapeutics: antibody cancer drug, 201710– collab €na discovery of TACA selective targeting antibodies |
2017-10-04 |
| Immatics–Amgen: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Hopp Group: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–SEVERAL: investment, 201710 financing round Series E $58m Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Strüngmann Group: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Immatics–Wellington Partners: investment, 201710 financing round Series E totalling $58m incl Hopp + Strüngmann + Wellington Partners + Amgen et al |
2017-10-04 |
| Lunaphore–Redalpine: investment, 201710 2nd financing round totalling CHF6m incl existing investor Redalpine Venture Partners |
2017-10-04 |
| Lunaphore–SEVERAL: investment, 201710 2nd financing round CHF6m incl Redalpine + Zühlke Ventures + Polytech Ecosystem et al. |
2017-10-04 |
| Body Labs–Amazon: investment, 201710 acquisition €na (estimate $50m-$70m) of Body Labs by Amazon |
2017-10-03 |
| Cullinan Oncology–F2 Ventures: investment, 201710 financing round Series A totalling $150m incl co-lead investor F2 Ventures |
2017-10-03 |
| Cullinan Oncology–SEVERAL: investment, 201710 financing round Series A $150m co-led by UBS Oncology Impact Fund (MPM Capital) + F2 Ventures |
2017-10-03 |
| Cullinan Oncology–UBS: investment, 201710 financing round Series A totalling $150m incl co-lead investor UBS Oncology Impact Fund managed by MPM |
2017-10-03 |
| Epiontis–Precision Medicine Group: investment, 201709 acquistion of Epiontis GmbH |
2017-09-30 |
| Eppendorf–Arburg: plastic moulding machine, 201709 supply of 100th Allrounder machine to Eppendorf Polymere GmbH |
2017-09-29 |
| Exscientia–Evotec: investment, 201709 investment €15m by Evotec AG to acquire minority stake in Exscientia Ltd |
2017-09-28 |
| Novartis–Univ California: drug discovery technology, 201709– collab establishment of Novartis-Berkeley Center for Proteomics & Chemistry Technologies |
2017-09-28 |
| Orgentec–Streck: laboratory equipment, 201709– distribution of Streck cell stabilisation + molecular products by Orgentec SASA in France |
2017-09-28 |
| Merlin Diagnostika–Bruker: investment, 201709 acquisition €na by Bruker |
2017-09-26 |
| Sonic Healthcare–Bruker: mass spectrometer, 201709 supply existent MLB is long-term user of MALDI Biotyper system |
2017-09-26 |
| Atriva Therapeutics–InSynchrony Ventures: investment, 201709 seed financing round 2nd tranche incl new investor InSynchrony Ventures |
2017-09-21 |
| Atriva Therapeutics–SEVERAL: investment, 201709 seed financing round 2nd tranche incl new investor InSynchrony Ventures |
2017-09-21 |
| Humabs BioMed–Vir Biotechnology: investment, 201709 acquisition of Humabs by Vir |
2017-09-21 |
| Juno Therapeutics–Celgene: investment, 201709 private placement $31.1m to Celgene with 758k shares at $41/share |
2017-09-20 |
| Juno Therapeutics–SEVERAL: investment, 201709 public offering $250.1m+$37.515m with 6.1m+915k shares at $41/share |
2017-09-20 |
| Nabriva–W2O Group: public relations, 201709 service existent PR by Pure Communications |
2017-09-20 |
| BioNTech–Akampion: public relations, 201709 service existent by Akampion |
2017-09-19 |
| Axiogenesis–Pluriomics: investment, 201709 merger into Ncardia |
2017-09-18 |
| Bruker–Bioinformatics Solutions: mass spectrometry software, 201709 collab existent using PEAKS Studio s/w for MS-based proteomics |
2017-09-18 |
| Bruker–Max Planck: mass spectrometry, –201709 collab developm of PASEF technology for timsTOF Pro MS for proteomics with Matthias Mann |
2017-09-18 |
| High-Tech Gründerfonds–Evonik: investment, 201709 investment existent in HTGF III fund |
2017-09-18 |
| Labiotech.eu–SEVERAL: investment, 201709 2nd financing round €6-digit led by Wille AG + incl Simon Bungers |
2017-09-18 |
| Labiotech.eu–Wille Finance: investment, 201709 2nd financing round totalling €6-digit incl new + lead investor Wille AG |
2017-09-18 |
| Nabriva–SEVERAL: investment, 201709 public offering $80m+$12m with 9.4m+1.4m ordinary shares at $6/share |
2017-09-18 |
| Numaferm–Evonik: investment, 201709 Evonik Venture Capital joins €7-digit seed financing round |
2017-09-18 |
| ThromboGenics–Novartis: investment, 201709–201801 equity investment €10m by Novartis after termination of Jetrea agreement |
2017-09-18 |
| Tolremo Therapeutics–SEVERAL: investment, 201709 seed financing round CHF2.4m |
2017-09-18 |
| BioBridges–Adecco: investment, 201709 acquisition €na of BioBridges by Adecco Group |
2017-09-14 |
| Evotec–MaRS Innovation: drug discovery, 201709– collab partnership LAB150 for early-stage projects out of Canadian academic institutions |
2017-09-14 |
| Ginkgo Bioworks–Bayer: investment, 201709– founding joint venture firm with $100m Series A from Ginkgo + BLSC + Viking Global Investors |
2017-09-14 |
| Ginkgo Bioworks–SEVERAL: investment, 201709– founding joint venture with Bayer with $100m Series A from Ginkgo + BLSC + Viking Global Investors |
2017-09-14 |
| Ginkgo Bioworks–Viking Global Investors: investment, 201709– founding Ginkgo/Bayer joint venture with $100m Series A from Ginkgo + BLSC + Viking |
2017-09-14 |
| Flagship Pioneering–Lipotype: lipid analysis, 201709c supply service lipid anaylsis for Flagship VentureLabs |
2017-09-13 |
| Genenta Science–SEVERAL: investment, 201709 financing round Series B €7m |
2017-09-13 |
| GreenLight Biosciences–SEVERAL: investment, 201709 financing round Series D $18m led by Fall Line Capital |
2017-09-13 |
| Sophia Genetics–SEVERAL: investment, 201709 financing round Series D $30m led by Balderton Capital |
2017-09-13 |
| Bayer–Berkeley Lights: cell line development, 201709– collab using Beacon platform for cell line development + antibody discovery |
2017-09-12 |
| DNA Script–Idinvest Partners: investment, 201711 financing round Series A totalling €11m incl existing investor Idinvest Partners |
2017-09-12 |
| DNA Script–Illumina: investment, 201711 financing round Series A totalling €11m incl lead + new investor Illumina Ventures |
2017-09-12 |
| DNA Script–Kurma: investment, 201711 financing round Series A totalling €11m incl existing + seed investor Kurma Partners |
2017-09-12 |
| DNA Script–Merck (DE): investment, 201711 financing round Series A totalling €11m incl new investor Merck Ventures BV |
2017-09-12 |
| DNA Script–SEVERAL: investment, 201711 financing round Series A €11m led by Illumina Ventures |
2017-09-12 |
| DNA Script–Sofinnova: investment, 201711 financing round Series A totalling €11m incl existing + seed investor Sofinnova Partners |
2017-09-12 |
| Ayoxxa–MC Services: public relations, 201709 service existent by MC Services AG |
2017-09-11 |
| Epigenomics–Cathay Fortune: credit, 201709 convertible bonds €7.1m net €6.5m to Cathay Fortune |
2017-09-08 |
| BRAIN Biotech–Hopp Group: investment, 201709 capital increase 1.641m new shares placed with new investor DAH Beteiligungs GmbH |
2017-09-07 |
| BRAIN Biotech–Hopp Group: investment, 201709 capital increase €28m with 1.641m new shares at €18.055 to new investor DAH Beteiligungs GmbH |
2017-09-07 |
| Rigontec–Merck (US): investment, 201709– acquisition €115m cash upfront + €349m milestones |
2017-09-06 |
| Amal Therapeutics–BioMedPartners: investment, 201709 financing round Series B first closing totalling €8m incl co-lead investor BioMedPartners |
2017-09-05 |
| Amal Therapeutics–Boehringer: investment, 201709 financing round Series B first closing totalling €8m incl co-lead investor BIVF |
2017-09-05 |
| Amal Therapeutics–Helsinn: investment, 201709 financing round Series B first closing totalling €8m incl co-lead investor Helsinn Investment Fund |
2017-09-05 |
| Amal Therapeutics–High-Tech Gründerfonds: investment, 201709 financing round Series B first closing totalling €8m incl co-investor HTGF |
2017-09-05 |
| Amal Therapeutics–Schroders: investment, 201709 financing round Series B first closing totalling €8m incl co-investor Schroder Adveq |
2017-09-05 |
| Amal Therapeutics–SEVERAL: investment, 201709 financing round Series B first closing €8m co-led by BIVF + BioMedPartners + Helsinn |
2017-09-05 |
| Amal Therapeutics–VI Partners: investment, 201709 financing round Series B first closing totalling €8m incl co-investor VI Partners |
2017-09-05 |
| Immunic–SEVERAL: investment, 201709 financing round Series A extension €10m led by LSP bringing total Series A to €31.7m |
2017-09-05 |
| Metabolomic Discoveries–Metabolon: investment, 201709 acquisition €na of Metabolomic Discoveries GmbH by Metabolon Inc |
2017-09-05 |
| Pharnext–MC Services: public relations, 201709 service existent investor relations Europe by MC Services |
2017-09-05 |
| Boehringer–Allcyte: drug discovery, 201709– collab using Pharmacoscopy ex vivo drug response profiling platform for BI oncology candidates |
2017-09-04 |
| Amcure–Germany (govt): grant, 201708 BMBF research grant €1.75m to advance clinical lead candidate AMC303 |
2017-08-31 |
| Angiex–Merck (DE): drug development services, 201708– supply BioReliance End-to-End Solutions for developm of ADC therapy of Angiex Inc |
2017-08-29 |
| Apeiron–EU (govt): credit, 201708– EIB EFSI loan €25m to support developm of cancer drugs |
2017-08-28 |
| Kite Pharma–Gilead: investment, 201708–201710 acquisition $11.9b cash tender offer $180/share |
2017-08-28 |
| Natrix Separations–Merck (DE): investment, 201708– acquisition €na of Natrix Separations by Merck ANNOUNCED |
2017-08-28 |
| Aurealis Pharma–SEVERAL: investment, 201708 financing round Series A CHF5.6m from private investors + Finnvera + Tekes |
2017-08-25 |
| Novartis–Xoma: IL-1 beta antibodies, 201708– license $26m upfront + $5m investment + milestones + royalties ww rights to gevokizumab + IL-beta Ab IP |
2017-08-25 |
| Labfolder–Germany (govt): business development, 201708– supply service support in US with German Accelerator Life Sciences programme |
2017-08-24 |
| Macrophage Pharma–Merck (DE): investment, 201708 financing round Series A extension with new investor Merk Ventures |
2017-08-23 |
| Batavia–UGA Biopharma: cell line development, –201708 collab devleopm of 2 enzmye expressing monoclonal cell lines for biopharma production |
2017-08-22 |
| CRISPR Therapeutics–Partners HealthCare: cell therapy, 201708– collab research + license option 2y w MGHCC develop cancer T cell therapies w CRISPR |
2017-08-22 |
| Lilly–Topas Therapeutics: immuno modulatory compounds, 201708– collab €na multi-y research + option agreem |
2017-08-22 |
| Micro-Sphere–Ramarketing: public relations, 201708– service by Ramarketing |
2017-08-22 |
| AstraZeneca–Ethris: mRNA-based therapeutics, 201708– collab research 5y w €25m upfront + funding + milestones using SNIM®RNA technology |
2017-08-21 |
| Ethris–MacDougall Biomedical Communications: public relations, 201708 service existent by MacDougall |
2017-08-21 |
| Rodos BioTarget–SEVERAL: investment, 201708 capital increase €800k via crowdfunding platform Aescuvest |
2017-08-18 |
| Biotecon–Bruker: mass spectrometer, 201708– distribution OEM of MALDI Biotyper platforms for food analysis in DACH region + Eastern Europe |
2017-08-16 |
| Monsanto–ToolGen: CRISPR technology, 201708– license ww €na for use of ToolGen’s CRISPR technology platform in agricultural products |
2017-08-16 |
| Roche–Mimetas: organ-on-a-chip technology, –201708 collab developm gut model on-a-chip using OrganoPlate platform |
2017-08-16 |
| Purdue Pharma–CellAct: cancer drug, 201708– acquisition ww developm + commerc rights to CAP7.1 by Mundipharma from CellAct |
2017-08-14 |
| Roivant–SEVERAL: investment, 201708 financing round $1.1b led by SoftBank Vision Fund + incl Dexxon investor group |
2017-08-09 |
| Roivant–SoftBank: investment, 201708 financing round totalling $1.1b incl new + lead investor SoftBank Vision Fund |
2017-08-09 |
| Diagnosticum (HU)–Bruker: food analysis, 201708 collab to form Hungarian Wine Consortium using NMR FoodScreener for wine analysis |
2017-08-08 |
| IFM Therapeutics–BMS: investment, 201708– acquisition two cancer assets for $300m upfront + up to $2.02b milestones |
2017-08-03 |
| Bruker–OTHER: immunoassay technology, 201708 acquisition €na of portable chip-based ELISA platform by Bruker |
2017-08-02 |
| Homology Medicines–HBM: investment, 201708 financing round Series B totalling $83.5m incl new + co-investor HBM Healthcare Investments |
2017-08-01 |
| Homology Medicines–Novartis: investment, 201708 financing round Series B totalling $83.5m incl new + co-investor Novartis |
2017-08-01 |
| Homology Medicines–SEVERAL: investment, 201708 financing round Series B $83.5m led by Deerfield Management |
2017-08-01 |
| Lyocontract–Lyomark Pharma: investment, 201708 acquisition of majority share in Lyocontract GmbH by Lyomark Pharma GmbH |
2017-08-01 |
| Aptuit–Evotec: investment, 201707–201708 acquisition $300m in cash of Aptuit from Welsh, Carson, Anderson & Stowe |
2017-07-30 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 37 38 39 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
